Imfinzi (durvalumab) Receives Positive CHMP Opinion in EU for PD-L1 expressing LA NSCLC patients
Shots:
- Imfinzi has been approved in unresectable PD-L1 expressing LA NSCLC patients treated with platinum-based CRT
- Approval is based post-hoc subgroup analyses by PD-L1 expression in addition to PFS & OS results of PACIFIC trial
- In 2018- AZ received recommendations for Stage III NSCLC US- Canada- Switzerland- India- and Japan based on PACIFIC trial
Ref: Astrazeneca | Image: Bloomberg
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
